打开APP

OrbiMed筹措7亿3千万美元投资生物技术产业

  1. OrbiMed
  2. 生物领域投资

来源:生物谷 2013-11-06 08:50

2013年11月5日讯 /生物谷BIOON/ --近两年来生物技术领域的投资一直不温不火,而作为生物技术领域投资领导者的OrbiMed公司最近进行了价值达7亿3千5百万美元的第五轮投资,其投资范围涉及到各个研究阶段的生物技术公司。公司初步预计将资助大约30个公司的研发项目,每个项目资助额度大约为1000万美元到5千万美元。这也表明OrbiMed公司对生物技术产业投资开始继续加码。

2013年11月5日讯 /生物谷BIOON/ --近两年来生物技术领域的投资一直不温不火,而作为生物技术领域投资领导者的OrbiMed公司最近进行了价值达7亿3千5百万美元的第五轮投资,其投资范围涉及到各个研究阶段的生物技术公司。公司初步预计将资助大约30个公司的研发项目,每个项目资助额度大约为1000万美元到5千万美元。这也表明OrbiMed公司对生物技术产业投资开始继续加码。

公司合伙人Jonathan Silverstein表示此次公司投资的一个特点是公司投资着眼于生物技术公司发展的各个阶段。作为世界上最大的生物技术产业投资公司,OrbiMed公司管理着近50亿美元的资金,公司目前投资了一系列公司如Adimab、Cleave Biosciences等公司。OrbiMed公司的这一举动是否能成为风险投资公司的风向标尚不得而知,但是众所周知今年许多生物技术公司进行IPO,在资本市场上获得了大量资金,这或许暗示明年风投领域将迎来新变化。(生物谷Bioon.com)

详细英文报道:

As biotech venture funding plods along, A-list investor OrbiMed has bagged $735 million for its 5th fund, cash earmarked for life sciences companies across all stages of development.

OrbiMed figures its latest haul can support about 30 portfolio companies across biopharma and med tech, fueling individual bets between $10 million and $50 million. And, unlike the many VCs debuting downsized new funds in the shadow of the downturn, OrbiMed's new purse far outweighs the $550 million it trotted out in 2010. That's an affirmation of OrbiMed's ability to keep returns flowing despite market conditions, General Partner Jonathan Silverstein said, and, in a sluggish fundraising environment, that makes all the difference to limited partners.

"What's important to note is that we've made money in all stages of development," Silverstein told FierceBiotech. "One of the things that attracted investors to the fund was that ability, no matter where the market goes."

OrbiMed is the world's largest life sciences-dedicated investor, and, with $5 billion under management, the New York firm has bankrolled some of the biggest names in biotech. Its portfolio includes in-demand developer Adimab and promising upstart Cleave Biosciences, and OrbiMed has pulled off some high-dollar exits, with Aragon Pharmaceuticals going to Johnson & Johnson ($JNJ) for up to $1 billion and Puma Biotech ($PBYI) going public in a $138 million IPO, to name just two. On the med tech side, OrbiMed is a backer of devicemaker Glaukos and prenatal diagnostics outfit Natera, two members of the 2013 FierceMedicalDevices Fierce 15.

With its new fund, OrbiMed is staying fairly agnostic as it hunts for new portfolio companies, Partner Carl Gordon said, looking for innovation in every life sciences sector from outfits of all sizes.

"We're willing to invest broadly, from startups all the way through revenue-based companies," Gordon said. "On the whole, we're looking for companies that are going to make a difference to the healthcare system."

Meanwhile, despite a bright second quarter, the world of biotech venture funding remains tepid at best, especially for early-stage companies. Last quarter, total venture dollars dropped 39% from the previous period with first-time financings plummeting by 56%, according to the latest MoneyTree Report.

But that swoon won't last much longer, Silverstein said.

"What will happen is that starting next year, there'll be a lot more VC funds raised as these IPOs of 2013 filter into everybody's returns," he said. "I think we're about to see a big rebound."

And he's not alone. OrbiMed's latest fund puts it among a growing list of venture stalwarts building up their war chests this year with faith in future innovation. NovaQuest just closed a $459 million fund for its patented late-stage financings, joining big-namers Third Rock, Atlas and Frazier Healthcare, which have debuted new life science-directed funds totaling more than $1 billion. Meanwhile, Versant Ventures is putting together another $200 million fund and the startup-focused 5AM Ventures is raising $240 million.

"This is an exciting time to launch our next fund, given the combination of the high rate of new FDA drug approvals, a vibrant IPO window and the accelerating level of innovation from companies across the life sciences investment universe," Gordon said

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->